PSTI Share Price

Open 1.53 Change Price %
High 1.56 1 Day 0.08 5.44
Low 1.52 1 Week 0.04 2.65
Close 1.55 1 Month 0.03 1.97
Volume 148738 1 Year 0.00 0.00
52 Week High 1.85
52 Week Low 0.71
PSTI Important Levels
Resistance 2 1.59
Resistance 1 1.57
Pivot 1.54
Support 1 1.53
Support 2 1.51
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Pluristem Therapeutics, Inc. (NASDAQ: PSTI)

PSTI Technical Analysis 3
As on 5th Dec 2016 PSTI Share Price closed @ 1.55 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.46 & Buy for SHORT-TERM with Stoploss of 1.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
PSTI Target for December
1st Target up-side 1.55
2nd Target up-side 1.6
3rd Target up-side 1.65
1st Target down-side 1.41
2nd Target down-side 1.36
3rd Target down-side 1.31
PSTI Other Details
Segment EQ
Market Capital 174166400.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pluristem.com
PSTI Address
PSTI
MATAM Advanced Technology Park
Building No. 5
Haifa, 31905
Israel
Phone: 972 7 4710 7171
Interactive Technical Analysis Chart Pluristem Therapeutics, Inc. ( PSTI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Pluristem Therapeutics, Inc.
PSTI Business Profile
Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stromal cell source. The placental adherent stromal cells (ASCs) are grown in the Company's PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.